Palatin Technologies - PTN Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.00
  • Forecasted Upside: 750.00%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$2.00
▲ +0.01 (0.50%)

This chart shows the closing price for PTN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Palatin Technologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PTN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PTN

Analyst Price Target is $17.00
▲ +750.00% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Palatin Technologies in the last 3 months. The average price target is $17.00, with a high forecast of $17.00 and a low forecast of $17.00. The average price target represents a 750.00% upside from the last price of $2.00.

This chart shows the closing price for PTN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Palatin Technologies. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/3/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/1/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
5/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$17.00
5/8/2024HC WainwrightReiterated RatingBuy ➝ Buy$17.00
5/2/2024HC WainwrightReiterated RatingBuy ➝ Buy$17.00
2/28/2024HC WainwrightLower TargetBuy ➝ Buy$70.00 ➝ $17.00
2/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$70.00
8/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$70.00
3/13/2023HC WainwrightReiterated RatingBuy$70.00
2/16/2023HC WainwrightReiterated RatingBuy$70.00
9/9/2022LADENBURG THALM/SH SHBoost TargetBuy$50.00
9/9/2022HC WainwrightBoost TargetBuy$70.00
9/8/2022HC WainwrightReiterated RatingBuy$70.00
3/8/2022HC WainwrightReiterated RatingBuy$125.00
11/24/2021HC WainwrightBoost TargetBuy$50.00 ➝ $125.00
9/30/2021LADENBURG THALM/SH SHReiterated RatingBuy$50.00
5/12/2020HC WainwrightReiterated RatingBuy$50.00
1/10/2020HC WainwrightLower TargetBuy$187.50 ➝ $50.00
11/13/2019HC WainwrightReiterated RatingBuy$187.50
9/13/2019HC WainwrightSet TargetBuy$200.00
6/24/2019HC WainwrightSet TargetBuy$200.00
(Data available from 5/27/2019 forward)

News Sentiment Rating

0.08 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/29/2023
  • 1 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
11/28/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/28/2023
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/27/2024
  • 7 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/26/2024
  • 1 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/27/2024
  • 4 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2024
  • 1 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
5/26/2024

Current Sentiment

  • 1 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Palatin Technologies logo
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL8177, an oral peptide formulation for treatment of ulcerative colitis, which entered Phase 2 clinical trials. The company was founded in 1986 and is based in Cranbury, New Jersey.
Read More

Today's Range

Now: $2.00
Low: $1.89
High: $2.07

50 Day Range

MA: N/A

52 Week Range

Now: $2.00
Low: $1.43
High: $5.65

Volume

259,900 shs

Average Volume

535,030 shs

Market Capitalization

$32.28 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Frequently Asked Questions

What sell-side analysts currently cover shares of Palatin Technologies?

The following Wall Street sell-side analysts have issued research reports on Palatin Technologies in the last twelve months: HC Wainwright, and StockNews.com.
View the latest analyst ratings for PTN.

What is the current price target for Palatin Technologies?

1 Wall Street analysts have set twelve-month price targets for Palatin Technologies in the last year. Their average twelve-month price target is $17.00, suggesting a possible upside of 750.0%. HC Wainwright has the highest price target set, predicting PTN will reach $17.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $17.00 for Palatin Technologies in the next year.
View the latest price targets for PTN.

What is the current consensus analyst rating for Palatin Technologies?

Palatin Technologies currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PTN will outperform the market and that investors should add to their positions of Palatin Technologies.
View the latest ratings for PTN.

What other companies compete with Palatin Technologies?

How do I contact Palatin Technologies' investor relations team?

Palatin Technologies' physical mailing address is 4B Cedarbrook Dr, CRANBURY, NJ 08512-3641, United States. The biopharmaceutical company's listed phone number is (609) 495-2200 and its investor relations email address is [email protected]. The official website for Palatin Technologies is www.palatin.com. Learn More about contacing Palatin Technologies investor relations.